As Moderna prioritizes maximizing the reach of its COVID-19 vaccine, Thursday’s announcement of the impending departure of longtime CMO Tal Zaks caps a transformational 14 months for the mRNA company and comes during a year when...

COVID-19 vaccine developers are taking multiple approaches to combat emerging SARS-CoV-2 variants, ranging from administering additional booster shots of authorized vaccines to developing variant-specific...

Moderna is taking a two-pronged approach to addressing potentially weakened vaccine protection against SARS-CoV-2 variants by evaluating an additional booster shot of its current vaccine — a solution...

The discussion at Thursday’s FDA advisory committee meeting on a COVID-19 vaccine from Moderna and NIH highlighted the increasing difficulties of conducting trials as more vaccines become authorized and...

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...

It took 322 days from the day Moderna produced the first dose of mRNA-1273 for the company to announce Monday that in a Phase III trial its vaccine had prevented 94.1% of symptomatic and 100%...

Contrasting comments from Pfizer management on Tuesday, Moderna promised full transparency with regard to interim results from its Phase III COVE study of COVID-19 vaccine mRNA-1273. The company pledged to report either a positive or...

New Phase I data suggest Moderna’s COVID-19 vaccine maintains its immunogenicity in elderly individuals better than two other leading vaccines. Assuming neutralizing antibodies are key determinants...

Partners Pfizer and BioNTech are now neck-and-neck with Moderna as both groups began pivotal testing Monday of their respective mRNA vaccines for COVID-19. Moderna Inc. (NASDAQ:MRNA) received additional funding from Operation Warp Speed, via BARDA,...

A clearer picture of the late-stage clinical development path for one of the most advanced COVID-19 vaccines is taking shape as Moderna shares additional details of its Phase III trial design for mRNA-1273. The main...